Expert Review of Anticancer Therapy

Article	Citations
Triple-negative breast cancer: promising prognostic biomarkers currently in development	76
TIM-3 pathway dysregulation and targeting in cancer	52
Molecular therapeutic targets in non-small cell lung cancer	43
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis	37
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy	30
The potential of PSMA-targeted alpha therapy in the management of prostate cancer	30
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies	28
TKIs in combination with immunotherapy for hepatocellular carcinoma	27
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer	26
The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review	26
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy	25
Asbestos-related cancers: the ‘Hidden Killer’ remains a global threat	25
Current radiotherapy techniques in NSCLC: challenges and potential solutions	24
Treatment of recurrent glioblastoma: state-of-the-art and future perspectives	23
Optimal treatment in locally advanced cervical cancer	22
The role of the microbiome in drug resistance in gastrointestinal cancers	21
The emerging role of antibody-drug conjugates in urothelial carcinoma	21
Pediatric relapsed acute myeloid leukemia: a systematic review	21
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies	20
New insights into ErbB3 function and therapeutic targeting in cancer	20
What is the best clinical approach to recurrent/refractory osteosarcoma?	20
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer	20
Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy	18
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review	18
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy	18

Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis	17
Gender discrepancies in bladder cancer: potential explanations	17
Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis	17
Pembrolizumab for advanced cervical cancer: safety and efficacy	17
A multimodal approach to cancer-related cachexia: from theory to practice	16
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy	16
COVID-19: how will this impact children with cancer, now and in the future?	15
Radiomics features as predictive and prognostic biomarkers in NSCLC	15
Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer	15
PARP inhibition in treatment of pancreatic cancer	14
MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review	14
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs	14
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors	14
Surgical management of intrahepatic cholangiocarcinoma	14
Should triple-positive breast cancer be recognized as a distinct subtype?	14
Apoferritin: a potential nanocarrier for cancer imaging and drug delivery	14
Cholangiocarcinoma: investigations into pathway-targeted therapies	13
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy	13
Palliative care for advanced gastric cancer	13
Melanoma immunotherapy: strategies to overcome pharmacological resistance	13
Osteolytic metastasis in breast cancer: effective prevention strategies	13
How can biosimilars change the trajectory of breast cancer therapy?	12
microRNAs as biomarkers of ovarian cancer	12
Immunosenescence, inflammaging, and cancer immunotherapy efficacy	12
The emerging role of PARP inhibitors in prostate cancer	12
Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer	12
Promising predictors of checkpoint inhibitor response in NSCLC	12
Neoadjuvant therapy for muscle-invasive bladder cancer	11
Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature	11
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	11
Pembrolizumab in the first-line treatment of advanced head and neck cancer	11
Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma	11
Prostate re-irradiation: current concerns and future perspectives	11
Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress	11
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions	11
The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review	11
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development	11
Radiotherapy in the era of COVID-19	11
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors	11
The diagnostic challenges of patients with carcinoma of unknown primary	11
Combined endocrine and targeted therapy in luminal breast cancer	11
Advances in systemic therapy for the first-line treatment of unresectable HCC	11
Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19	11
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence	10
Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives	10
The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments	10
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm	10
Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis	10
Amivantamab for the treatment ofEGFRexon 20 insertion mutant non-small cell lung cancer	9
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance	9

Advancements in predicting outcomes in patients with glioma: a surgical perspective	9
The potential of cystatin C as a predictive biomarker in breast cancer	9
Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature	9
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer	9
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem	9
Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets	9
The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies	9
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma	9
The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma	9
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy	9
Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method	9
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors	9
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma	8
Current clinical management of elderly patients with glioma	8
Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer	8
Treatment of cervical cancer: overcoming challenges in access to brachytherapy	8
Cemiplimab for locally advanced and metastatic basal cell carcinoma	8
Progress in determining response to treatment in gastrointestinal stromal tumor	8
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies	8
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype	8
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer	8
Immune checkpoint inhibition in classical hodgkin lymphoma	8
Detection ofMETexon 14 skipping mutations in non-small cell lung cancer: overview and community perspective	8
Evaluating new treatments for anaplastic thyroid cancer	8
A multidisciplinary approach to soft-tissue sarcoma of the extremities	8
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma	8
Development of chemotherapeutics for unresectable advanced esophageal cancer	7
Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy	7
Immune checkpoint inhibitors for recurrent endometrial cancer	7
Measurable residual disease in pediatric acute myeloid leukemia: a systematic review	7
Current developments in the combination therapy of relapsed/refractory multiple myeloma	7
Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?	7
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan	7
Factors associated with early lung cancer mortality: a systematic review	7
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide	7
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma	7
Therapeutic options in thymomas and thymic carcinomas	7
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma	7
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma	7
Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives	7
miRNA and mRNA expression profiling reveals potential biomarkers for metastatic cutaneous melanoma	7
Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis	7
Treatment options after first-line immunotherapy in metastatic NSCLC	7
High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL)	7
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer	7
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion	7
Bladder-sparing treatment options in localized muscle-invasive bladder cancer	7
Ribociclib plus fulvestrant in the treatment of breast cancer	7
The impact of nutritional status on pancreatic cancer therapy	7
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis	7
Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications	6
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement	6
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma	6
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy	6
Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature	6
Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor	6
Developments in personalized therapy for metastatic renal cell carcinoma	6
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype	6
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer	6
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives	6
Targeting the PI3K pathway in myeloproliferative neoplasms	6
The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma	6
Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity	6
Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene	6
EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy	6
Curative therapy for rectal cancer	6
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer	6
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer	6
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy	6
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview	6
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma	6
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy	6
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials	6
Glasdegib in newly diagnosed acute myeloid leukemia	6
Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract	6
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement	6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	6
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer	6
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation	5
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	5

Understanding resistance to immune checkpoint inhibitors in advanced breast cancer	5
Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma	5
Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years	5
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy	5
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity	5
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer	5
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis	5
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy	5
Current androgen receptor antagonists under investigation for resistant prostate cancer	5
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy	5
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	5
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer	5
Luteinized thecoma (thecomatosis) with sclerosing peritonitis: a systematic review of the literature of the last 25 years	5
Clinically-meaningful improvements in therapy for unresectable NSCLC	5
Overview and recent advances in the targeting of medulloblastoma cancer stem cells	5
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?	5
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma	5
Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel	5
A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials	5
Monoclonal antibodies as an addition to current myeloma therapy strategies	5
Clear cell sarcoma: state-of-the art and perspectives	5
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?	5
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?	4
A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer	4
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	4
The current clinical approach to difficult-to-treat basal cell carcinomas	4
Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma	4
Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety	4
Promising novel therapies for relapsed and refractory testicular germ cell tumors	4
The current status of gene therapy in bladder cancer	4
Addressing the problem of overtreatment in breast cancer	4
Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events	4
Oxygen therapy in traditional and immunotherapeutic treatment protocols of cancer patients: current reality and future prospects	4
Sex-based differences in outcomes of patients with HPV-positive versus HPV-negative oropharyngeal carcinoma: a population-based study	4
PARP inhibitors in prostate cancer: time to narrow patient selection?	4
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019	4
Hot topics in renal cancer pathology: implications for clinical management	4
Medullary thyroid carcinoma: a narrative historical review	4
Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy	4
Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy	4
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy	4
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)	4
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light	4
Multidisciplinary approaches to cancer cachexia: current service models and future perspectives	4
How to face cancer treatment in the COVID-19 era	4
Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?	4
New nonchemotherapy treatment options for cutaneous T-cell lymphomas	4
Pitfalls and controversies in pathology impacting breast cancer management	4
Immunotherapy as a partner for HER2-directed therapies	4
Real-world experience with trabectedin for the treatment of recurrent ovarian cancer	4
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need	4
Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis	4
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma	4
The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia	4
Non-metastatic castration-resistant prostate cancer: current status and future directions	4
Identifying effective drug combinations for patients with acute myeloid leukemia	4
Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis	4
Direct KRAS inhibition: progress, challenges, and a glimpse into the future	4
A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer	4
Effect of primary tumor resection on survival in patients with asymptomatic unresectable metastatic colorectal cancer: a systematic review and meta-analysis	4
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance	3
Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC	3
What is the role of PARP inhibitors in pancreatic cancer?	3
The use of real-world evidence to support FDA post-approval study requirements for oncology drugs	3
A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022	3
Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma	3
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer	3
Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics	3
Immunotherapy in urothelial cancer: current status and future directions	3
The role of immunotherapy in fusion-driven lung cancer	3
Management of breast cancer diagnosed during pregnancy: global perspectives	3
The current clinical approach to newly diagnosed uterine cancer	3
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	3
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials	3
On the road to treatment-free remission in chronic myeloid leukemia: what about ‘the others’?	3
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan	3
Improving the accuracy of prognostication in chronic myelomonocytic leukemia	3
Diagnostic accuracy of arterial spin labeling in differentiating between primary central nervous system lymphoma and high-grade glioma: a systematic review and meta-analysis	3
Elranatamab: a new promising BispAb in multiple myeloma treatment	3
Clinical implications of lung neuroendocrine neoplasm classification	3
Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach	3
Patient stratification in hepatocellular carcinoma: impact on choice of therapy	3
Naltrexone at low doses (LDN) and its relevance to cancer therapy	3
The changing landscape of stage III lung cancer: a literature review	3
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	3
Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy	3
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	3
Diagnostic accuracy of diffusion-weighted imaging in differentiating glioma recurrence from posttreatment-related changes: a meta-analysis	3
Lymph nodal radiotherapy in breast cancer: what are the unresolved issues?	3
Current and emerging therapies for localized high-risk prostate cancer	3
Radiolabeled FAPI in pancreatic cancer: can it be an additional value in the management of patients?	3
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	3
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	3
Proton therapy for thoracic malignancies: a review of oncologic outcomes	3